All In Biotech

Drug Trial Radar · NCT06807268

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

A 16-WEEK, MULTICENTER, INTERVENTIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ABROCITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 151 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

151

Actual

Start

Jul 24, 2025

Primary completion

May 2, 2027

Study completion May 2, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Feb 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks. The study will last for about 24 weeks in total.

Conditions

  • Eczema

Interventions

  • AbrocitinibDrug

    Abrocitinib administered as liquid oral suspension.

  • PlaceboOther

    Placebo administered as liquid oral suspension.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at Week 12Time frame: At week 12
  2. Response based on achieving ≥75% improvement from baseline in the Eczema Area and Severity Index (EASI)-75 at Week 12Time frame: At week 12

Locations

47 sites in 8 countries. Site status is shown where the registry gives one.

  • Cahaba Dermatology & Skin Health Center, LLC

    Birmingham, Alabama

  • Arkansas Research Trials

    North Little Rock, Arkansas

  • Investigational Drug Service - Rady Childrens Hospital-San Diego

    San Diego, California

  • University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm

    San Diego, California

  • Solutions Through Advanced Research

    Jacksonville, Florida

  • Ada West Research

    Meridian, Idaho

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Saint Louis University - Department of Dermatology

    St Louis, Missouri

  • Medical University of South Carolina - Department of Dermatology

    Charleston, South Carolina

  • Medical University of South Carolina - South Carolina Translational Research Nexus Clinic

    Charleston, South Carolina

  • Medical University of South Carolina - Walton Research Building

    Charleston, South Carolina

  • Tribe Clinical Research, LLC

    Greenville, South Carolina

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas

  • Shanghai Children's Hospital

    Shanghai, China

  • Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine

    Shanghai, China

  • Beijing Children's hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Shenzhen Children's Hospital

    Shenzhen, Guangdong, China

  • Hunan Children's Hospital

    Changsha, Hunan, China

  • Dermatology Hospital of Jiangxi Province

    Nanchang, Jiangxi, China

  • Shanghai Children's Hospital

    Shanghai, Shanghai Municipality, China

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, China

  • Universitätsklinikum Münster

    Münster, North Rhine-Westphalia, Germany

  • Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden

    Dresden, Saxony, Germany

  • University of Pecs

    Pécs, Hungary

  • Pécsi Tudományegyetem Klinikai Központ

    Pécs, Baranya, Hungary

  • Trial Pharma Kft.

    Békéscsaba, Bekes County, Hungary

  • Szegedi Tudományegyetem Bőrgyógyászati és Allergológiai Klinika

    Szeged, Csongrád-csanád, Hungary

  • Clinexpert Kft.

    Budapest, Pest County, Hungary

  • Fukuoka National Hospital

    Fukuoka, Japan

  • Saruta Dermatology Clinic

    Fukuoka, Japan

  • Queen's square Medical Facilities Queen's square Dermatology and Allergology

    Yokohama, Kanagawa, Japan

  • Dermatology and Ophthalmology Kume Clinic

    Sakai, Osaka, Japan

  • Sasamoto Children's Clinic

    Setagaya-ku, Tokyo, Japan

  • Servicios Hospitalarios de México S.A. de C.V. (Hospital Angeles Chihuahua)

    Chihuahua City, Mexico

  • Hospital Infantil de México Federico Gómez

    Mexico City, Mexico City, Mexico

  • Eukarya Pharmasite S.C.

    Monterrey, Nuevo León, Mexico

  • Arke SMO S.A. de C.V.

    Veracruz, Veracruz, Mexico

  • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka cywilna

    Krakow, Lesser Poland Voivodeship, Poland

  • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak

    Lodz, Łódź Voivodeship, Poland

  • LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska

    Lublin, Lublin Voivodeship, Poland

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.